Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) - Vuky, J; Vasant Balar, A; Castellano, D E (Journal of Clinical Oncol, 2018)
et al.